Compare Stocks: MBRX, RYM, SCYX, and AGFY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGFY Agrify	$21.65 -6.5%	$22.18	$13.22 ▼ $48.84	$94.36M	9.96	31,892 shs	12,189 shs
MBRX Moleculin Biotech	$0.72 -13.8%	$1.17	$0.16 ▼ $15.75	$13.93M	1.92	638,370 shs	1.93 million shs
RYM RYTHM	$21.73 -6.2%	$22.07	$14.00 ▼ $53.65	$47.18M	9.44	14,082 shs	12,189 shs
SCYX SCYNEXIS	$4.84 +3.0%	$4.80	$3.53 ▼ $10.48	$48.16M	1.11	69,127 shs	30,409 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGFY Agrify	-6.52%	-17.52%	+5.15%	-21.90%	-45.02%
MBRX Moleculin Biotech	0.00%	+0.72%	+25.15%	-72.92%	-92.50%
RYM RYTHM	0.00%	-15.51%	+2.36%	-21.34%	+2,172,499,900.00%
SCYX SCYNEXIS	0.00%	-8.68%	-5.47%	+14.42%	-41.83%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGFY Agrify	$21.65 -6.5%	$22.18	$13.22 ▼ $48.84	$94.36M	9.96	31,892 shs	12,189 shs
MBRX Moleculin Biotech	$0.72 -13.8%	$1.17	$0.16 ▼ $15.75	$13.93M	1.92	638,370 shs	1.93 million shs
RYM RYTHM	$21.73 -6.2%	$22.07	$14.00 ▼ $53.65	$47.18M	9.44	14,082 shs	12,189 shs
SCYX SCYNEXIS	$4.84 +3.0%	$4.80	$3.53 ▼ $10.48	$48.16M	1.11	69,127 shs	30,409 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGFY Agrify	-6.52%	-17.52%	+5.15%	-21.90%	-45.02%
MBRX Moleculin Biotech	0.00%	+0.72%	+25.15%	-72.92%	-92.50%
RYM RYTHM	0.00%	-15.51%	+2.36%	-21.34%	+2,172,499,900.00%
SCYX SCYNEXIS	0.00%	-8.68%	-5.47%	+14.42%	-41.83%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGFY Agrify	0.00	N/A	N/A	N/A
MBRX Moleculin Biotech	2.33	Hold	$3.00	319.58% Upside
RYM RYTHM	1.00	Sell	N/A	N/A
SCYX SCYNEXIS	2.33	Hold	$33.00	581.82% Upside

Current Analyst Ratings Breakdown

Latest MBRX, RYM, SCYX, and AGFY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2026	MBRX Moleculin Biotech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$3.00
8/13/2026	RYM RYTHM	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/13/2026	SCYX SCYNEXIS	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$24.00 ➝ $33.00
7/31/2026	SCYX SCYNEXIS	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/24/2026	SCYX SCYNEXIS	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	MBRX Moleculin Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/10/2026	SCYX SCYNEXIS	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/26/2026	SCYX SCYNEXIS	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGFY Agrify	$12.26M	3.54	N/A	N/A	$10.47 per share	2.07
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	$4.69 per share	N/A
RYM RYTHM	$17.28M	2.74	N/A	N/A	$6.06 per share	3.58
SCYX SCYNEXIS	$19.22M	2.51	N/A	N/A	$9.07 per share	0.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGFY Agrify	-$41.75M	-$22.65	N/A	N/A	N/A	-424.11%	-185.90%	-72.67%	N/A
MBRX Moleculin Biotech	-$33.56M	-$7.13	N/A	N/A	N/A	N/A	-143.51%	-24.53%	11/12/2026 (Estimated)
RYM RYTHM	-$33.26M	-$10.53	N/A	N/A	N/A	-6.20%	-12.57%	-2.60%	N/A
SCYX SCYNEXIS	-$8.61M	-$2.09	N/A	N/A	N/A	-41.79%	-44.15%	-32.61%	11/4/2026 (Estimated)

Latest MBRX, RYM, SCYX, and AGFY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	MBRX Moleculin Biotech	-$1.55	-$1.40	+$0.15	-$1.40	N/A	N/A
8/10/2026	Q2 2026	SCYX SCYNEXIS	-$0.5067	$0.63	+$1.1367	$0.63	$0.08 million	$0.24 million
8/4/2026	Q2 2026	RYM RYTHM	N/A	$0.09	N/A	$0.09	N/A	$23.02 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGFY Agrify	N/A	N/A	N/A	N/A	N/A
MBRX Moleculin Biotech	N/A	N/A	N/A	N/A	N/A
RYM RYTHM	N/A	N/A	N/A	N/A	N/A
SCYX SCYNEXIS	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGFY Agrify	1.43	2.64	2.52
MBRX Moleculin Biotech	N/A	0.94	0.94
RYM RYTHM	N/A	0.59	0.56
SCYX SCYNEXIS	N/A	9.65	9.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGFY Agrify	5.98%
MBRX Moleculin Biotech	15.52%
RYM RYTHM	5.98%
SCYX SCYNEXIS	54.37%

Insider Ownership

Company	Insider Ownership
AGFY Agrify	2.16%
MBRX Moleculin Biotech	18.04%
RYM RYTHM	3.48%
SCYX SCYNEXIS	4.09%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGFY Agrify	140	2.00 million	1.96 million	Not Optionable
MBRX Moleculin Biotech	20	19.48 million	15.96 million	Not Optionable
RYM RYTHM	140	2.18 million	2.10 million	N/A
SCYX SCYNEXIS	60	9.95 million	9.54 million	Optionable

MBRX, RYM, SCYX, and AGFY Headlines

Recent News About These Companies

SCYNEXIS Names Sanjay Subramanian as CFO

September 10 at 9:29 PM | finance.yahoo.com

Scynexis Names Sanjay Subramanian CFO

September 10 at 11:29 AM | rttnews.com

SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer

September 10 at 8:00 AM | globenewswire.com

SCYNEXIS (NASDAQ:SCYX) Stock Price Passes Above Fifty Day Moving Average - Here's What Happened

September 9, 2026 | marketbeat.com

SCYNEXIS to Participate in Upcoming Investor Conferences

September 1, 2026 | globenewswire.com

SCYNEXIS (NASDAQ:SCYX) Shares Pass Below 200 Day Moving Average - Should You Sell?

September 1, 2026 | marketbeat.com

SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

August 25, 2026 | globenewswire.com

SCYNEXIS (NASDAQ:SCYX) Upgraded at Wall Street Zen

August 16, 2026 | marketbeat.com

SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 10, 2026 | tmcnet.com

SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

June 30, 2026 | globenewswire.com

SCYNEXIS Shareholders Approve Governance and Equity Plan Changes

June 26, 2026 | tipranks.com

SCYNEXIS Inc.

June 24, 2026 | marketwatch.com

SCYNEXIS Announces One-for-Eight Reverse Stock Split

May 22, 2026 | globenewswire.com

SCYNEXIS (SCYX) price target increased by 20.73% to 4.28

May 14, 2026 | msn.com

SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 11, 2026 | globenewswire.com

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

May 6, 2026 | globenewswire.com

SCYNEXIS Raises $40 Million in Strategic Private Placement

April 19, 2026 | theglobeandmail.com

SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics Transcript

March 31, 2026 | seekingalpha.com

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney ...

March 31, 2026 | markets.businessinsider.com

Why did SCYX stock jump 10% in pre-market today?

March 31, 2026 | msn.com

Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million

March 31, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBRX, RYM, SCYX, and AGFY Company Descriptions

Agrify NASDAQ:AGFY

$21.65 -1.51 (-6.52%)

As of 09/11/2026

Agrify Corporation offers hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. It offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. The company also provides associated services comprising consulting, engineering, and construction. In addition, the company offers hydrocarbon, alcohol, solventless, post-processing, and lab equipment, as well as provides indoor farming solutions. In addition, it offers equipment and services in a contract and purchase order. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Troy, Michigan.

Moleculin Biotech NASDAQ:MBRX

$0.72 -0.11 (-13.85%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$0.74 +0.03 (+3.50%)

As of 09/11/2026 07:59 PM Eastern

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

RYTHM NASDAQ:RYM

$21.72 -1.44 (-6.20%)

Closing price 09/11/2026 03:58 PM Eastern

Extended Trading

$21.66 -0.07 (-0.30%)

As of 09/11/2026 07:30 PM Eastern

Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.

SCYNEXIS NASDAQ:SCYX

$4.84 +0.14 (+2.98%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$4.89 +0.05 (+1.14%)

As of 09/11/2026 07:30 PM Eastern

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MBRX, RYM, SCYX, and AGFY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MBRX, RYM, SCYX, and AGFY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MBRX, RYM, SCYX, and AGFY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBRX, RYM, SCYX, and AGFY Company Descriptions

Agrify NASDAQ:AGFY

Moleculin Biotech NASDAQ:MBRX

RYTHM NASDAQ:RYM

SCYNEXIS NASDAQ:SCYX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MBRX, RYM, SCYX, and AGFY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MBRX, RYM, SCYX, and AGFY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MBRX, RYM, SCYX, and AGFY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBRX, RYM, SCYX, and AGFY Company Descriptions

Agrify NASDAQ:AGFY

Moleculin Biotech NASDAQ:MBRX

RYTHM NASDAQ:RYM

SCYNEXIS NASDAQ:SCYX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools